Emerging roles for mammalian target of rapamycin inhibitors in the treatment of solid tumors and hematological malignancies
NZ Khokhar, JK Altman… - Current opinion in …, 2011 - journals.lww.com
NZ Khokhar, JK Altman, LC Platanias
Current opinion in oncology, 2011•journals.lww.comThe rapalogs are the first mTOR inhibitors to show promising, yet modest, antitumor effects.
To fully exploit the potential of targeting this pathway, it will be important to better understand
the mechanisms of action and precise targets of the various inhibitors. Moreover, definition
of biomarkers of susceptibility and identification of predictors and/or correlates to drug
resistance will substantially advance this area.
To fully exploit the potential of targeting this pathway, it will be important to better understand
the mechanisms of action and precise targets of the various inhibitors. Moreover, definition
of biomarkers of susceptibility and identification of predictors and/or correlates to drug
resistance will substantially advance this area.
Summary
The rapalogs are the first mTOR inhibitors to show promising, yet modest, antitumor effects. To fully exploit the potential of targeting this pathway, it will be important to better understand the mechanisms of action and precise targets of the various inhibitors. Moreover, definition of biomarkers of susceptibility and identification of predictors and/or correlates to drug resistance will substantially advance this area.
Lippincott Williams & Wilkins